Home / Intelligence

Type
  • All
  • Analyst Reports
  • Blog
  • Briefs
  • Case Studies
  • Podcasts
  • Scientific Publications
  • Webinars
  • White Papers
Featured Topic
  • All
  • AIML
  • Analytics
  • APAC
  • Benchmarking
  • Biosimilars
  • CAR-T
  • Cell and Gene Therapy
  • Commercial Operations
  • Competitive Intelligence
  • Contract Analytics
  • Corporate Strategy
  • COVID-19
  • Customer Engagement
  • Data Management
  • Digital Therapeutics
  • Diversity
  • Emerging Life Sciences
  • Europe
  • Evidence Strategy (HEOR)
  • Field Force
  • Forecasting
  • Generative AI
  • Incentive Compensation
  • Inflation Reduction Act
  • Insights
  • International
  • LatAm
  • Launch and Brand Excellence
  • Learning and Development
  • Market Research
  • Marketing
  • Medical Affairs
  • MedTech
  • New Product Planning
  • NRDL
  • Omnichannel
  • Oncology
  • Patient Centricity
  • Patient Finding
  • Patient Services
  • Performance Tracking
  • Pricing and Access
  • Product Demos
  • Rare Disease
  • Real-World Evidence
  • Scientific Publications
  • Sustainability
  • Talent Acquisition and Retention
  • United States
  • Value Communication
Search
Snowflake Webinar - patient outcome chart with exponential arrow

Webinars

RWD Expertise x Technology = Enhanced Patient Outcomes

March 27, 2025 | 12:00 - 12:45 PM ET

The addition of real-world data (RWD) to other data streams through technology allows the patient impact to be magnified many times. Combined with PMR, RWD can drive exceptional insights and accuracy in demand assessments, segmentation, message testing, market mapping and ATUs. Amplified with GenAI and solutions like Real Insights and RealWorldEDGE, the range of RWD-powered use cases broadens even further.

Sign Up Now

White Papers

How to Approach Asset Valuation in Pharma & Biotech:

Pharma and biotech companies are innovation drivers at the frontlines of research and development. To fund and support this promising science, there is a great need for partnerships and mergers and acquisitions (M&A) to drive the growth/pipeline of the industry. For these collaborative relationships to occur, understanding the value of a company’s underlying assets is of the utmost importance. Since Trinity’s founding, multiple pharma and biotech clients have relied on its expertise in forecast and valuing assets. These engagements have…

Read Now

Sign up for the latest intelligence

By signing up, you are agreeing to our Privacy Policy.

By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.